Navigation Links
Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain
Date:5/6/2009

MONTREAL, May 6 /PRNewswire/ - Aegera Therapeutics is pleased to announce the initiation of a Phase 2a, proof-of-concept, clinical trial for AEG33773, a novel, orally bio-available small molecule therapeutic addressing the under-served market of painful diabetic neuropathy.

The Phase 2a study, entitled A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Comparing the Safety and Efficacy of AEG33773 versus Placebo in Patients with Painful Diabetic Peripheral Neuropathy will evaluate the efficacy, safety and tolerability of three dose levels of AEG33773 in diabetic patients suffering from significant neuropathic pain. This study is underway in Canada and Aegera will soon initiate trial sites in the Unites States, where the IND has recently cleared the FDA regulatory review process, and also in Europe, where the regulatory documents are now under review by the appropriate regulatory authorities.

"We are very excited about this first Phase 2 study for AEG33773 which has demonstrated robust preclinical in vivo data in multiple models of neuropathic and inflammatory pain. Furthermore, AEG33773 could have the potential to treat chronic pain conditions well beyond painful diabetic neuropathy." commented Dr. Jacques Jolivet, M.D., Senior Vice President Clinical Development of Aegera.

"With the successful conclusion of the Phase 1 safety studies for AEG33773 and the initiation of the first Phase 2a trial in diabetic patients suffering from significant neuropathic pain, we are now focused on successfully completing this trial while identifying an appropriate development partner; this will ensure that our novel agent is developed rapidly and effectively for its first indication while exploring additional indications so as to expand this franchise on a global basis." added Dr. Michael J. Berendt, Aegera's President and CEO.

About Aegera Therapeutics Inc. (www.aegera.com)

Aegera Therapeutics is a clinical stage biotechnology company focused on developing targeted therapeutics for major unmet medical needs. Aegera has three programs in clinical development. In addition to AEG33773, Aegera is developing

    - AEG35156 targets the key anti-apoptotic protein XIAP, and is in
      multiple randomized Phase II clinical trials;
    - HGS1029(AEG40826) is a small molecule pan-IAP inhibitor in Phase 1
      development. It has demonstrated very promising preclinical activity
      and is partnered with Human Genome Sciences, Inc. (Nasdaq:  HGSI) for o
      ncology in all countries except Japan.

'/>"/>
SOURCE AEGERA THERAPEUTICS INC.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
2. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
3. Aegera Therapeutics welcomes two experienced executives to its board of directors
4. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
5. Aegera Therapeutics phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
6. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
7. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
8. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
9. Spectrum Pharmaceuticals Initiates Second Registrational Phase 3 Clinical Trial for EOquin(R) in Patients With Non-Invasive Bladder Cancer
10. XTL Biopharmaceuticals Initiates Phase IIb Clinical Trial of Bicifadine for the Treatment of Diabetic Neuropathic Pain
11. Nventa Initiates HspE7 Phase 1 Cervical Dysplasia Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2017)... ... July 27, 2017 , ... A luxury car manufacturer ... popular corporate team building events this summer. , Each team gathered ... competition to whet their palettes. Three teams were then formed, and each ...
(Date:7/27/2017)... RESEARCH TRIANGLE PARK, N.C., July 27, 2017 ... today announced its financial results for the second ... "Our second quarter total net revenues ... level ever," said Martine Rothblatt, Ph.D., United Therapeutics ... believe that Orenitram is well-positioned given the large ...
(Date:7/26/2017)... ... 2017 , ... CardioWise, Inc. , is pleased to ... analysis software, and an associated pending patent from Johns Hopkins Technology Ventures through ... uses high resolution cardiac CT to analyze cardiac wall motion that provides extraordinary ...
(Date:7/26/2017)... ... July 26, 2017 , ... Franz ... Semantic Graph Database technology for Knowledge Graphs, today announced Gruff v7.0 , ... Gruff provides novice users and graph experts the ability to visually build queries ...
Breaking Biology Technology:
(Date:4/13/2017)... According to a new market research report "Consumer IAM Market ... Authorization), Service, Authentication Type, Deployment Mode, Vertical, and Region - Global Forecast ... from USD 14.30 Billion in 2017 to USD 31.75 Billion by 2022, ... ... MarketsandMarkets Logo ...
(Date:4/11/2017)... , Apr. 11, 2017 Research and ... Market 2017-2021" report to their offering. ... The global eye tracking market to grow at a ... report, Global Eye Tracking Market 2017-2021, has been prepared based on ... covers the market landscape and its growth prospects over the coming ...
(Date:4/11/2017)... 2017 NXT-ID, Inc. (NASDAQ:   NXTD ... the appointment of independent Directors Mr. Robin D. Richards ... of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , Chief ... to their guidance and benefiting from their considerable expertise as ...
Breaking Biology News(10 mins):